Breaking News, Collaborations & Alliances

Codexis Earns $6.5 Million Technology Transfer Milestone Payment From GSK

Agreement grants GSK a license to use Codexis' CodeEvolver platform technology to develop novel enzymes

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Proten engineering company Codexis Inc. has completed Wave 2 of the transfer of its proprietary CodeEvolver protein engineering platform technology to GlaxoSmithKline (GSK) in the third quarter of 2015. Codexis expects to receive a $6.5 million payment from GSK for completion of this milestone in the fourth quarter of 2015. Codexis has received a $6 million upfront payment and a $5 million Wave 1 technology transfer milestone payment from GSK since announcing the technology collaboration and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters